Cyclo Therapeutics Business Update and 2020 Results

 - Multiple value-driving milestones expected throughout 2021

- Trappsol® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study

- Company expects to commence enrollment in pivotal Phase 3 study of Trappsol® Cyclo™ for NPC in Q2 2021

- IND filing for Trappsol® Cyclo™ Alzheimer’s Disease program on track for H2 2021

- Strengthened balance sheet with exercise of warrants

https://www.businesswire.com/news/home/20210315005155/en/Cyclo-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results